Showing 1 - 6 results of 6 for search 'Karin Hägerbrand', query time: 0.03s Refine Results
  1. 1
    RUBY® – a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties

    RUBY® – a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties by Barnabas Nyesiga, Mattias Levin, Anna Säll, Anna Rosén, Kim Jansson, Sara Fritzell, Karin Hägerbrand, Dietmar Weilguny, Laura von Schantz

    Published 2024-12-01
    Get full text
    Article
  2. 2
    Transcriptional profiling demonstrates altered characteristics of CD8+ cytotoxic T‐cells and regulatory T‐cells in TP53‐mutated acute myeloid leukemia

    Transcriptional profiling demonstrates altered characteristics of CD8+ cytotoxic T‐cells and regulatory T‐cells in TP53‐mutated acute myeloid leukemia by Milad Abolhalaj, Viktor Sincic, Henrik Lilljebjörn, Carl Sandén, Alar Aab, Karin Hägerbrand, Peter Ellmark, Carl A. K. Borrebaeck, Thoas Fioretos, Kristina Lundberg

    Published 2022-08-01
    Get full text
    Article
  3. 3
    Early Pharmacodynamic Changes Measured Using RNA Sequencing of Peripheral Blood from Patients in a Phase I Study with Mitazalimab, a Potent CD40 Agonistic Monoclonal Antibody

    Early Pharmacodynamic Changes Measured Using RNA Sequencing of Peripheral Blood from Patients in a Phase I Study with Mitazalimab, a Potent CD40 Agonistic Monoclonal Antibody by Hampus Andersson, Aastha Sobti, David Gomez Jimenez, Yago Pico de Coaña, Sumeet Vijay Ambarkhane, Karin Hägerbrand, Karin Enell Smith, Malin Lindstedt, Peter Ellmark

    Published 2023-09-01
    Get full text
    Article
  4. 4
    837 Combination treatment with ATOR-4066, a Neo-X-Prime™ bispecific antibody targeting CD40 and CEACAM5, and anti-PD-1 reverses T cell exhaustion in vitro

    837 Combination treatment with ATOR-4066, a Neo-X-Prime™ bispecific antibody targeting CD40 and CEACAM5, and anti-PD-1 reverses T cell exhaustion in vitro by Malin Lindstedt, Peter Ellmark, Karin Hägerbrand, Sara Fritzell, Anette Sundstedt, David Gomez Jimenez, Anneli Nilsson, Lill Ljung, Mattias Levin, Mona Celander, Ida Uddbäck, Amulya Krishna Shetty, Hampus Andersson

    Published 2023-11-01
    Article
  5. 5
    Distinct Infiltration of T Cell Populations in Bladder Cancer Molecular Subtypes

    Distinct Infiltration of T Cell Populations in Bladder Cancer Molecular Subtypes by Viktor Sincic, Ken F. Arlenhold, Sarah Richtmann, Henrik Lilljebjörn, Pontus Eriksson, Gottfrid Sjödahl, Mats Wokander, Karin Hägerbrand, Peter Ellmark, Thoas Fioretos, Carl A. K. Borrebaeck, Fredrik Liedberg, Kristina Lundberg

    Published 2024-05-01
    Get full text
    Article
  6. 6
    Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies

    Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies by Malin Lindstedt, Peter Ellmark, Lennart Greiff, Karin Hägerbrand, Laura von Schantz, Mia Thagesson, Doreen Werchau, Kristine Smedenfors, Anna Rosén, Anette Sundstedt, Adnan Deronic, Lill Ljung, Mattias Levin, Laura Varas, Anna Säll, Christina Sakellariou, Barnabas Nyesiga, David Gomez Jimenez, Mona Celander, Deniz Bölükbas, Fredrika Carlsson

    Published 2022-11-01
    Get full text
    Article

Search Tools: